A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO  TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER

drug protocol number
WO43571
drug sponsor
Roche
drug study
Giredestrant , Phesgo
drug trial site
King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase